網膜生物製剤市場の規模、シェア、成長分析、薬剤クラス別、適応症別、流通チャネル別、地域 - 産業予測、2025～2032年

網膜生物製剤の世界市場規模は、2023年に229億米ドルと評価され、2024年の246億4,000万米ドルから2032年には442億7,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは7.6％で成長する見通しです。

網膜疾患、特に加齢黄斑変性（AMD）、糖尿病性網膜症、網膜静脈閉塞症の有病率の増加は、人口の高齢化に伴う喫緊の課題です。バイオテクノロジーの進歩は、革新的な治療法への需要を喚起しており、特に遺伝子治療や細胞治療が人気を集めている網膜生物製剤ではその傾向が顕著です。Foundation Fighting BlindnessやAmerican Macular Degeneration Foundationなどの著名な団体が、一般市民の認知度を高め、重要な研究イニシアチブを支援しています。特に中国、ブラジル、インドなどの新興市場は、ヘルスケア・インフラの改善と糖尿病罹患率の上昇に後押しされ、大きな成長を遂げようとしています。全体として、網膜生物製剤市場は、治療の進歩、認知度の向上、これらの疾患に対する世界の取り組みによって、拡大が見込まれています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 技術の進歩
• 貿易分析
• 顧客と購買基準の分析

網膜生物製剤市場規模：薬剤クラス別

• 市場概要
• VEGF-A拮抗薬
• TNF-α阻害剤

網膜生物製剤市場規模：適応症別

• 市場概要
• 黄斑変性
• 糖尿病黄斑浮腫
• 糖尿病網膜症
• ぶどう膜炎
• その他

網膜生物製剤市場規模：流通チャネル別

• 市場概要
• 機関投資家向け販売
• 小売薬局
• 通信販売薬局
• 小売販売

網膜生物製剤市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• F. Hoffmann-La Roche Ltd（Switzerland）
• Regeneron Pharmaceuticals Inc.（USA）
• AbbVie Inc.（USA）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• Amgen Inc.（USA）
• Johnson & Johnson（USA）
• Biogen Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Bristol-Myers Squibb Company（USA）
• Sanofi Genzyme（France）
• Santen Pharmaceutical Co., Ltd.（Japan）
• Bausch & Lomb Incorporated（USA）
• Adverum Biotechnologies, Inc.（USA）
• MeiraGTx Holdings plc（UK）
• Oxurion NV（Belgium）
• Kodiak Sciences Inc.（USA）
• Clearside Biomedical, Inc.（USA）
• Neurotech Pharmaceuticals, Inc.（USA）
• Opthea Limited（Australia）

結論と推奨事項

Global Retinal Biologics Market size was valued at USD 22.9 billion in 2023 and is poised to grow from USD 24.64 billion in 2024 to USD 44.27 billion by 2032, growing at a CAGR of 7.6% during the forecast period (2025-2032).

The increasing prevalence of retinal diseases, notably age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion, is a pressing concern driven by aging populations. Advances in biotechnology have catalyzed demand for innovative treatment options, particularly in retinal biologics, where gene therapy and cell-based therapies are gaining traction. Notable organizations, including the Foundation Fighting Blindness and the American Macular Degeneration Foundation, are enhancing public awareness and supporting critical research initiatives. Emerging markets, especially in countries like China, Brazil, and India, are poised for significant growth, fueled by improved healthcare infrastructure and rising diabetes rates. Overall, the retinal biologics market is primed for expansion, driven by advancements in treatment, increasing awareness, and a concerted global effort to address these conditions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Retinal Biologics Market Segmental Analysis

Global Retinal Biologics Market is segmented by Drug Class, Indication, Distribution Channel and region. Based on Drug Class, the market is segmented into VEGF-A Antagonists and TNF-a Inhibitors. Based on Indication, the market is segmented into Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Uveitis and Others. Based on Distribution Channel, the market is segmented into Institutional Sales, Retail Pharmacies, Mail Order Pharmacies and Retail Sales. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Retinal Biologics Market

One of the primary drivers of the Global Retinal Biologics market is the alarming rise in vision-related issues, particularly in the United States. According to data from the Centers for Disease Control and Prevention, millions are diagnosed with diabetic retinopathy, with many at risk of developing further complications that could severely affect their eyesight. The increasing incidence of this condition is expected to boost the demand for effective treatments, thereby propelling significant growth in the market. As a result, the escalating need for retinal biologics is anticipated to create a robust pathway for advancements and investment in this sector.

Restraints in the Global Retinal Biologics Market

One of the significant restraints in the Global Retinal Biologics market is the high cost associated with these therapies. These biologic drugs can be prohibitively expensive, limiting access for individuals in developing countries who struggle to afford them. Additionally, the complexity involved in the manufacturing and commercialization of retinal biologics, coupled with stringent regulatory requirements, poses further challenges. This combination of factors not only restricts the market potential but also creates barriers for patients needing these crucial treatments, ultimately hindering overall market growth and accessibility to life-changing therapies for those in need around the world.

Market Trends of the Global Retinal Biologics Market

The Global Retinal Biologics market is witnessing a significant trend towards genetic treatment approaches, driven by recent advancements in gene therapy research for retinal diseases, particularly inherited retinal dystrophies. These innovative therapies are transforming the landscape of retinal biologic drugs, offering targeted solutions that address the root causes of these conditions rather than just alleviating symptoms. As a result, the market is expected to experience robust growth, fueled by increasing investments in R&D, promising clinical trial outcomes, and a rising awareness of genetic therapies among patients and healthcare professionals. This shift underscores a broader movement towards personalized medicine in ophthalmology.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement
• Trade Analysis
• Customer & Buying Criteria Analysis

Global Retinal Biologics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• VEGF-A Antagonists
• TNF-a Inhibitors

Global Retinal Biologics Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Macular Degeneration
• Diabetic Macular Edema
• Diabetic Retinopathy
• Uveitis
• Others

Global Retinal Biologics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Institutional Sales
• Retail Pharmacies
• Mail Order Pharmacies
• Retail Sales

Global Retinal Biologics Market Size & CAGR (2025-2032)

• North America (Drug Class, Indication, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi Genzyme (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch & Lomb Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx Holdings plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxurion NV (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurotech Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Opthea Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations